FDA Clearance Tracker · P130021-S155
Evolut FX+ TAV, Evolut FX DCS, Evolut FX LS
Last checked: Nov 20, 2026Latest source record: Mar 22, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Mar 22, 2024
Approved
Time to decision
56 days
Received Jan 26, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P130021-S155
- Device name
- Evolut FX+ TAV, Evolut FX DCS, Evolut FX LS
- Applicant
- Medtronic, Inc.
- Applicant location
- Miinneapolis, MN
- Received
- Jan 26, 2024
- Decided
- Mar 22, 2024
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P130021
Device type
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
Approval for design and manufacturing modifications to the Evolut FX System to incorporate larger openings in the stent frame. The device, as modified, will be marketed under the trade name Evolut FX+ System.
Source documents
Other decisions for Medtronic, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K263596 · Decided Oct 29, 2026 · 29 days after receipt
Device type: Catheter, Cannula And Tubing, Vascular, Cardiopulmonary Bypass (DWF) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.